Management of Renal Tumors by Image-Guided Radiofrequency Ablation: Experience in 105 Tumors

Aims In this article we present our experience with radiofrequency ablation (RFA) in the treatment of 105 renal tumors. Materials and Methods RFA was performed on 105 renal tumors in 97 patients, with a mean tumor size of 32 mm (11–68 mm). The mean patient age was 71.7 years (range, 36–89 years). The ablations were carried out under ultrasound (n = 43) or CT (n = 62) guidance. Imaging follow-up was by contrast-enhanced CT within 10 days and then at 6-monthly intervals. Multivariate analysis was performed to determine variables associated with procedural outcome. Results Eighty-three tumors were completely treated at a single sitting (79%). Twelve of the remaining tumors were successfully re-treated and a clinical decision was made not to re-treat seven patients. A patient with a small residual crescent of tumor is under follow-up and may require further treatment. In another patient, re-treatment was abandoned due to complicating pneumothorax and difficult access. One patient is awaiting further re-treatment. The overall technical success rate was 90.5%. Multivariate analysis revealed tumor size to be the only significant variable affecting procedural outcome. (p = 0.007, Pearson χ²) Five patients had complications. There have been no local recurrences. Conclusion Our experience to date suggests that RFA is a safe and effective, minimally invasive treatment for small renal tumors.     

Applying the theory of constraints in health care: Part 1--The philosophy

The imperative to improve both technical and service quality while simultaneously reducing costs is quite clear. The Theory of Constraints (TOC) is an emerging philosophy that rests on two assumptions: (1) systems thinking and (2) if a constraint "is anything that limits a system from achieving higher performance versus its goal," then every system must have at least one (and at most no more than a few) constraints or limiting factors. A constraint is neither good nor bad in itself. Rather, it just is. In fact, recognition of the existence of constraints represents an excellent opportunity for improvement because it allows one to focus ones efforts in the most productive area--identifying and managing the constraints. This is accomplished by using the five focusing steps of TOC: (1) identify the system's constraint; (2) decide how to exploit it; (3) subordinate/synchronize everything else to the above decisions; (4) elevate the system's constraint; and (5) if the constraint has shifted in the above steps, go back to step 1. Do not allow inertia to become the system's constraint. TOC also refers to a series of tools termed "thinking processes" and the sequence in which they are used.     

Genetic mapping of the copper toxicosis locus in Bedlington terriers to dog chromosome 10, in a region syntenic to human chromosome region 2p13- p16

Abnormal hepatic copper accumulation is recognized as an inherited disorder in man, mouse, rat and dog. The major cause of hepatic copper accumulation in man is a dysfunctional ATP7B gene, causing Wilson disease (WD). Mutations in the ATP7B genes have also been demonstrated in mouse and rat. The ATP7B gene has been excluded in the much rarer human copper overload disease non-Indian childhood cirrhosis, indicating genetic heterogeneity. By investigating the common autosomal recessive copper toxicosis (CT) in Bedlington terriers, we have identified a new locus involved in progressive liver disease. We examined whether the WD gene ATP7B was also causative for CT by investigating the chromosomal co-localization of ATP7B and C04107, using fluorescence in situ hybridization (FISH). C04107 is an anonymous microsatellite marker closely linked to CT. However, BAC clones containing ATP7B and C04107 mapped to the canine chromosome regions CFA22q11 and CFA10q26, respectively, demonstrating that WD cannot be homologous to CT. The copper transport genes CTR1 and CTR2 were also excluded as candidate genes for CT since they both mapped to canine chromosome region CFA11q22. 2-22.5. A transcribed sequence identified from the C04107-containing BAC was found to be homologous to a gene expressed from human chromosome 2p13-p16, a region devoid of any positional candidate genes.      

Bymixer provides on-line calibration of measurement of CO2 volume exhaled per breath

The measurement of CO₂ volume exhaled per breath can be determined during anesthesia by the multiplication and integration of tidal flow and . During side-stream capnometry, must be advanced in time by transport delay (TD), the time to suction gas through the sampling tube. During ventilation, TD can vary due to sample line connection internal volume or flow rate changes. To determine correct TD and measure accurate during actual ventilation, TD can be iteratively adjusted (TD_ADJ) until /tidal volume equals measured in a mixed expired gas collection (J. Appl. Physiol. 72:2029–2035, 1992). However, is difficult to measure during anesthesia because CO₂ is absorbed in the circle circuit. Accordingly, we implemented a bypass flow-mixing chamber device (bymixer) that was interposed in the expiration limb of the circle circuit and accurately measured over a wide range of conditions of ventilation of a test lung-metabolic chamber (regression slope=1.01;R ²=0.99). The bymixer response (time constant) varied from 18.1±0.03 sec (12.5 l/min ventilation) to 66.7±0.9 sec (2.5 l/min). Bymixer was used to correctly determine TD_ADJ (without interrupting respiration) to enable accurate measurement of over widely changing expiratory flow patterns.     

Sub-acute changes in lesion conspicuity and geometry following MR-guided radiofrequency ablation

PURPOSE: To evaluate MR signal and lesion zone volume evolution through the sub-acute phase following image-guided radiofrequency (RF) thermal ablation. MATERIALS AND METHODS: For many tissues, including muscle and liver, thermal lesions that result from RF heating have a characteristic two-boundary appearance featuring an inner core (zone I) surrounded by a hyper-intense margin (zone II) and normal tissue (zone III), found in both T(2) and contrast enhanced (CE) T(1)-weighted MR images, both immediately post-ablation and four days later. First, we compared corresponding points between manually segmented zone boundaries apparent in T(2)- and CE T(1)-weighted images. Second, we examined the contrast-to-noise ratio (CNR) between all zone combinations. Third, we quantified the volume of zone I, zone II, and the entire lesion using a three-dimensional lesion geometry model fitted to segmented images. RESULTS: On a slice-by-slice basis, no statistically significant differences were found between zone boundaries apparent in T(2) and CE T(1)-weighted images. The contrast to noise ratio (CNR) of zone I vs. zone II, zone I vs. background muscle, and zone II vs. background muscle was always equal or greater for T(2)-weighted images than for CE T(1)-weighted images. In addition, by day four, zone II significantly increased in intensity compared to background muscle. The median Zone I volume increase was 44.2% (42.6%) using T(2) weighted images and 55.5% (68.7% interquartile range) using CE T(1)- weighted images. This expansion likely corresponds to an enlargement of the ablated, coagulative necrosis, region. The median Zone II volume increase was 15.0% (42.6%) using T(2)- weighted images 1.5% (38.8%) using CE T(1)-weighted images. CONCLUSIONS: 1) There are no significant differences between the apparent zone boundaries in T(2)- and CE T(1)-weighted images; 2) CNR is equal or greater for T(2)-weighted images as compared to CE T(1)-images; and 3) both the inner and outer lesion zone volumes typically increase several days post-ablation.     

Bed usage in a Dublin teaching hospital: a prospective audit

Aims and methods  

We prospectively audited inpatient bed use in our hospital for the first three months of this year. While 70% (mean age 54±20.8 years) of our patients went home on the day they were medically discharged, 30% (mean age 70.3±18.3 years) remained in the hospital awaiting step-down facilities. The total of 486 bed days occupied by overstaying patients would if available, have allowed treatment of 54% more patients without any increase in the hospital complement of beds, preventing the cancellation of elective procedures and preventing patients remaining on trolleys overnight.     

Poor response to recombinant erythropoietin is associated with loss of T-lymphocyte CD28 expression and altered interleukin-10 production.

BACKGROUND: Recombinant erythropoietin (Epo) therapy is well established as an effective treatment for the anaemia of end-stage renal disease. However, 5-10% of such patients do not respond adequately and an important contributory factor to this is chronic inflammation. METHODS: The present study compares the circulating T-cell phenotypes of haemodialysis patients who respond poorly to Epo with those who respond well, along with normal controls. Isolated peripheral blood mononuclear cells were labelled with immunofluorescent monoclonal antibodies to surface antigens and analysed by flow cytometry. In vitro mononuclear cell cytokine secretion was also studied in the three subject groups. The cells were cultured for 48 h either without stimulus, with lipopolysaccharide or with monoclonal antibodies to CD3 and CD28. RESULTS: C-reactive protein levels were increased in poor responders to Epo (18.6 +/- 20.7 mg/l) compared with good responders (8.7 +/- 8.0 mg/l) and normal controls (3.8 +/- 1.1 mg/l). Patients responding poorly to Epo had increased circulating levels of CD4+/CD28- and CD8+/CD28- T-cells compared with patients responding well to Epo and normal controls. Unstimulated mononuclear cells from poor responders showed increased in vitro generation of interleukin-10 (IL-10) compared with both patients responding well to Epo and normal controls. Additionally, IL-10 generation stimulated by monoclonal antibodies to CD3 and CD28 was increased in poor responders compared with normal controls. CONCLUSIONS: These findings suggest that patients responding poorly to Epo may show enhanced immune activation as manifest by changes in both T-cell function and phenotype.